These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12717587)

  • 21. Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
    Pariser DM; Gordon KB; Papp KA; Leonardi CL; Kwon P; Compton PG; Rundle AC; Walicke PA; Lebwohl M
    J Cutan Med Surg; 2005 Dec; 9(6):303-12. PubMed ID: 16699904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
    Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
    J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.
    Hamilton T; Menter A; Caro I; Compton P; Sobell J; Papp KA
    Drug Saf; 2008; 31(8):715-26. PubMed ID: 18636790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efalizumab].
    Descamps V
    Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):666-78. PubMed ID: 17053736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efalizumab in the treatment of psoriasis.
    Gupta AK; Cherman AM
    J Cutan Med Surg; 2006; 10(2):57-68. PubMed ID: 17241576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II.
    Papp KA; Camisa C; Stone SP; Caro I; Wang X; Compton P; Walicke PA; Gottlieb AB
    J Cutan Med Surg; 2005 Dec; 9(6):313-23. PubMed ID: 16699903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efalizumab: an overview.
    Leonardi CL
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S98-104. PubMed ID: 12894132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial.
    Sterry W; Stingl G; Langley RG; Zacharie H; Lahfa M; Giannetti A; Ferrándiz C; Sinclair R; Saurat JH;
    J Dtsch Dermatol Ges; 2006 Nov; 4(11):947-56. PubMed ID: 17081270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.
    Antoniou C; Stefanaki I; Stratigos A; Avgerinou G; Stavropoulos P; Potouridou I; Polidorou D; Moustou AE; Kosmadaki M; Katsambas AD
    Br J Dermatol; 2007 Apr; 156 Suppl 2():12-6. PubMed ID: 17371318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
    Ortonne JP; Shear N; Shumack S; Henninger E;
    BMC Dermatol; 2005 Dec; 5():13. PubMed ID: 16359548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis.
    Toth DP; Papp K; Gratton D
    Dermatol Ther; 2008; 21 Suppl 3():S6-14. PubMed ID: 19076630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial.
    Lotti T; Chimenti S; Katsambas A; Ortonne JP; Dubertret L; Licu D; Simon J
    Arch Drug Inf; 2010 Mar; 3(1):9-18. PubMed ID: 20428228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efalizumab for the treatment of moderate to severe plaque psoriasis.
    Jordan JK
    Ann Pharmacother; 2005 Sep; 39(9):1476-82. PubMed ID: 15998666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.
    Cather JC; Cather JC; Menter A
    Expert Opin Biol Ther; 2003 Apr; 3(2):361-70. PubMed ID: 12662148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects.
    Sun YN; Lu JF; Joshi A; Compton P; Kwon P; Bruno RA
    J Clin Pharmacol; 2005 Apr; 45(4):468-76. PubMed ID: 15778428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current concepts and review of efalizumab in the treatment of psoriasis.
    Leonardi CL
    Dermatol Clin; 2004 Oct; 22(4):427-35, ix. PubMed ID: 15450338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.